Working groups

book for sale

Participants at the first meeting of the Working Group, Geneva 27-28 April 2017


WG Member area:
 to access the Working Group documents please click this link.

Drug-Induced Liver Injury (DILI)

Background

The incidence of drug induced liver injury (DILI) is a growing challenge because of the ever-increasing number of drugs used in medical care. DILI is responsible for more than 10% of all cases of acute liver failure, posing a major clinical and regulatory challenge. In a recent and well-executed population-based study, the crude annual incidence of DILI was 19.1 cases per 100,000 persons (95% CI, 1.54-23.3).

The clinical pattern of DILI is diverse and can mimic almost any form of liver disease, ranging from asymptomatic elevation in aminotransferases to severe disease such as cirrhosis or acute hepatitis leading to acute liver failure, making it difficult to establish an easy and early diagnosis. DILI remains largely unpredictable and is not amenable to efficient preventive measures.

In many instances, the hepatotoxic potential of a medicine can only be recognized once a product is on the market, and DILI is one of the most frequent reasons for withdrawal of products from the market and modification of labelling. Being an important cause of mortality and liver transplantation, and a leading cause of attrition in drug development, DILI remains a public health issue of great importance which needs additional international consensus guidance.

Working Group objectives

In 2017, CIOMS launched a Working Group composed of key stakeholders, including regulators, academia and industry partners, to address the present knowledge and practice gaps related to drug-induced liver injury (DILI). The group will formulate pragmatic, consensus-based recommendations to address the issues described above.

Progress

  • 1st meeting held on  27–28 April 2017 in Geneva, Switzerland (minutes)
  • 2nd meeting held on 14–15 November 2017 in Málaga, Spain (minutes)
  • 3rd meeting  held on 8–9 May 2018 in Reykjavík, Iceland (minutes)
  • 4th meeting held on 27–28 November 2018 in Aix-en-Provence, France (minutes)
  • 5th meeting held on 15–16 May 2019 in Tallinn, Estonia (minutes)

Since July 2019, five WG members have worked together as editorial team with support from the CIOMS Secretariat. The team has met twelve times by teleconference to work on the draft WG report. The draft was circulated to the Working Group on 15 April for comment, and was finalized in line with comments received. Publication is imminent.

—-

CIOMS Working Groups usually take 2-4 years to finalize their guidance and recommendations. Most groups hold two in-person meetings per year, with telework in between. The groups make use of collaborative efforts and capitalize on existing initiatives in order to provide output that is as comprehensive as possible, does not duplicate other efforts and has added value.

CIOMS MEETINGS

Upcoming Meetings

20 - 21 October 2020

Amsterdam, Netherlands

7th Meeting Working Group XI Patient Involvement in Development/Safe Use Medicines

23 - 24 September 2020

Geneva, Switzerland

3rd Meeting Working Group XIII Real-World Data & Evidence in Regulatory Decision-Making

08 - 09 September 2020

Virtual meeting

3rd meeting of WG XII Benefit-Risk Balance for Medicinal Products

25 - 26 August 2020

Virtual meeting

3rd meeting of MedDRA Labelling Groupings Working Group

20 - 21 August 2020

Virtual meeting

8th meeting of Clinical Research in Resource-Limited Settings Working Group

Recent Meetings